Case Study

Scale-up of PolyCYPs Reactions

Scale-up of PolyCYP reactions

Once a target metabolite or oxidised derivative has been synthesised by one or more PolyCYPs enzymes in the screening kit, a scale-up reaction with the best performing isoform is performed in order to access mg amounts of material for MetID and biological testing. The quickest and most cost-effective route for generating low mg amount of product is through the use of scale-up vials. Higher amounts of product can be generated using either a recombinant E.coli cell paste or through fermentation of a recombinant streptomyces clone expressing the isoform responsible for the biotransformation.

In this client case study, milligram amounts of specific oxidised products of two compounds were required. Both screening and scale-up reactions were conducted by Hypha for the client and the extract provided to the client for purification. Scale-up reactions were performed using 500 ml of disrupted E.coli cell pellet of PolyCYPs 196 and 152, dosed at 100 mg/L substrate, formulated with a cyclodextrin. Both reactions resulted in >50% turnover of the substrate. PolyCYPs reactions were also compared with biotransformations achieved from exposing the substrate to a panel of 16 wild type microbes, proven to be talented at metabolising a wide variety of drug compounds.

Scale up of polycyps reactions case study
679C860C-F15F-4CF4-AE4B-E3468A9F4726Created with sketchtool.

Clean background

The target metabolite was produced in a “clean background” by PolyCYP 196, making purification straightforward.

679C860C-F15F-4CF4-AE4B-E3468A9F4726Created with sketchtool.

Targeted production

Further and competing metabolism occurred in the whole cell microbial route, including production of glucuronides and a further oxidised metabolite.

For compound 1, several monohydroxylated metabolites were formed with the cleanest biotransformation to the target product achieved by PolyCYP 196. For compound 2, a single monohydroxylated target product was produced by PolyCYPs enzymes only, with PolyCYP 152 giving the best conversion. Other minor products were also of interest.

Related Resources

Introducing oxygen into a drug candidate late in the optimisation process has several applications including exploration of SAR (structure-activity relationships) and the ability to access derivatives that may possess superior properties such as improved metabolic stability and LLE (ligand-lipophilicity efficiency). Biocatalysis can provide access to chemical space in a complementary manner to chemical synthesis and provide a “one-experiment” solution to accessing multiple derivatives in parallel. This poster illustrates the application of a new biocatalysis kit, PolyCYPs®, to enable parallel synthesis of hydroxylated derivatives of drugs.

Access a brochure on Hypha’s PolyCYPs+ kits. The kits contain 20 enzymes effective for producing a wide range of phase 1 metabolites. As well as 18 PolyCYPs enzymes, the kit also contains human aldehyde oxidase (AOX1) and the main human hepatic flavin-containing monooxygenase (FMO3), with other human FMO isoforms also available from Hypha.

In this case study at least 2 mg of a monohydroxylated metabolite (M4), originally observed in rat liver microsomes, was required by a US pharma company. Using PolyCYPs, the target metabolite was supplied to the client together with a Certificate of Analysis within 22 days from receipt of order, exemplifying the short timelines achievable using PolyCYPs to access CYP-derived metabolites.

Ready to begin? Our scientists are available to talk through your requirements

Contact Us

Subscribe to our newsletter and blog!

Newsletter Signup
Which do you wish to signup for?

Don't forget to subscribe to our newsletter and blog!

Newsletter Signup
Which do you wish to signup for?